Turning the focus to ongoing research, an expert on upper gastric cancer discusses novel targets being investigated in clinical trials and the evolving treatment landscape.
Case: A 60-Year-Old Man with Stage IV Gastric Adenocarcinoma
Clinical Presentation:
Initial Clinical Workup and Diagnosis:
Current Treatments:
This is a video synopsis/summary of a Case-Based Peer Perspectives series featuring David Zhen, MD.
The treatment landscape for HER2-positive gastric cancer is rapidly evolving. In the first-line setting, the KEYNOTE-811 trial investigated the addition of pembrolizumab to chemotherapy plus trastuzumab, the current standard of care. Despite an initial accelerated approval based on impressive objective response rates, the final analysis revealed a survival benefit only in patients with a PD-L1 combined positive score of 1% or above, leading to a recent FDA indication change.
In the second-line setting, the antibody-drug conjugate (ADC) trastuzumab deruxtecan has shown impressive results compared with standard chemotherapy, overcoming HER2 resistance through the bystander effect, where the drug conjugate leaks into HER2-negative cells.
Ongoing trials are examining the role of immunotherapy in earlier-stage settings, with data on pathological complete response rates, but longer-term data on disease-free survival are needed.
The SPOTLIGHT and GLOW trials demonstrated the benefit of combining the monoclonal antibody zolbetuximab, which targets Claudin-18.2, with FOLFOX (leucovorin, fluorouracil, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) in the first-line setting for Claudin 18.2-expressing cancers. An FDA approval is expected soon, leading to the development of novel therapies like ADCs and chimeric antigen receptor T-cell therapies for progressive disease after targeted agents.
Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.
PD-L1 Provides Valid Biomarker for Nivolumab/Chemo in Gastric Cancer
February 28th 2024In a discussion with Targeted Oncology, Michael Gibson, MD, PhD, discusses the benefits of using a patient’s PD-L1 combined positive score to determine if they are given nivolumab and chemotherapy to treat their gastric cancer.
Read More
Optimal Results: Neoadjuvant Durvalumab and Chemotherapy Drive Improvement in Gastric/GEJ Cancers
January 19th 2024The combination of neoadjuvant FLOT with durvalumab demonstrated enhanced pathological complete response compared to sole chemotherapy in individuals with resectable gastric and GEJ cancers, regardless of geographical location.
Read More
FDA Issues Complete Response Letter to Zolbetuximab BLA in GI Cancer
January 9th 2024The FDA has issued a complete response letter to the biologics license application of zolbetuximab for patients with advanced, HER2-negative, claudin 18.2-positive gastric or gastoesophageal junction adenocarcinoma.
Read More
FDA Approves Pembrolizumab/Chemo for Gastric and GEJ Adenocarcinoma
November 16th 2023Pembrolizumab and fluoropyrimidine- and platinum-containing chemotherapy are now FDA-approved for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Read More